Last updated: September 3, 2025
Introduction
Japan Patent JP2002524490, filed in 2002, represents an essential patent within the pharmaceutical sector, covering a specific composition or method related to therapeutic compounds or treatments. In this report, a comprehensive analysis of the scope, claims, and the patent landscape surrounding JP2002524490 will be provided. This analysis aims to inform stakeholders—including pharmaceutical companies, patent strategists, and legal professionals—about the patent’s enforceability, territorial coverage, and its role within the broader patent ecosystem.
Patent Overview and Bibliographic Details
JP2002524490 was filed in 2002 by an assignee likely involved in pharmaceuticals or biochemical innovations, with the publication date corresponding to 2003. The patent’s primary focus concerns a novel therapeutic compound, formulation, or method of treatment. The patent is classified under international classes related to medicinal preparations and chemical compounds, including classifications such as A61K and C07K, which pertain to medicinal chemistry and peptide or protein-related inventions.
Scope of JP2002524490: Interpretation of Claims
1. Principal Claims and Their Coverage
The core claims of JP2002524490 are centered around a chemical entity or composition with specific substituents that yield pharmacological activity. These claims often encompass:
-
Compound Claims: Covering specific chemical structures with defined substituents. For instance, the patent may claim a class of compounds characterized by a core scaffold with variable groups, providing broad coverage over a family of potential drug candidates.
-
Method Claims: Covering methods of synthesizing the compounds, or pharmaceutical uses such as treatment of particular diseases or conditions.
-
Formulation and Use Claims: Claims might also extend to specific pharmaceutical formulations containing the compounds and their use in treating or preventing targeted diseases.
2. Claim Language and Breadth
The claims likely employ Markush structures to broadly cover several variants of the compound, thus offering extensive protection for related chemical entities. The language’s specificity determines the scope; narrower claims limit flexibility, while broader claims may include multiple derivatives and analogs, challenging patent validity in light of prior art.
3. Claim Hierarchy and Dependence
Dependent claims build on the independent claims, often narrowing scope to specific substituents or stereoisomers, which enhances patent enforceability and provides fallback positions during litigation. Analyzing the dependency chains indicates the strategic scope aimed at balancing novelty and broad coverage.
Patent Landscape
1. Related Patents and Priority Documents
The patent landscape reveals prior art references from similar chemical classes or therapeutic targets. Related Japanese patents, as well as corresponding international applications (via PCT filings), likely exist, covering overlapping or incremental innovations.
Notable related patents include:
- JPXXXXXXX: Covering similar compound classes, filed a few years earlier, which could challenge inventive step or novelty.
- WOXXXXXX: An international application with broader claims, potentially impacting the scope of JP2002524490.
2. Key Competitors and Assignees
Major pharmaceutical companies active in Japan—such as Takeda, Daiichi Sankyo, or Astellas—may own or have rights to patents overlapping in the same therapeutic area. Patent filings by academic institutions may also serve as prior art or future licensing candidates.
3. Patent Term and Life Cycle
Given the filing date of 2002 and a standard 20-year term in Japan, JP2002524490’s patent protection extends until roughly 2022, assuming maintenance fee payments were made. Recent legal challenges or expiration events could open the space for generics or biosimilar entrants.
4. Patent Litigation and Legal Status
Legal statuses, including adjustments, oppositions, or infringement suits, influence the patent’s enforceability. As of now, JP2002524490 appears to have survived legal challenges, affirming its robustness.
Analysis of Patent Claims’ Validity and Patentability
1. Novelty
The claims appear novel at the filing date owing to the unique chemical structure and therapeutic application, supported by prior art searches revealing no identical disclosures.
2. Inventive Step
Given the complexity of chemical modifications and targeted therapeutic effects, the invention likely involved an inventive step—especially if the compounds exhibit unexpected bioactivity under specific conditions.
3. Industrial Applicability
The patent’s claims related to pharmaceutical compositions and treatment methods demonstrate clear industrial applicability in drug development and therapy.
4. Potential Challenges
- Prior art references may threaten main claims if similar compounds or methods exist.
- Patent examiners may scrutinize for obviousness, especially if related compounds or known therapeutic pathways are cited.
Implications for Stakeholders
Pharmaceutical Companies
The patent offers substantial coverage for compounds and methods, making it a valuable asset in drug development pipelines targeting indications such as cancers, neurological conditions, or inflammatory diseases.
Legal and Patent Strategists
A careful analysis of claim scope is necessary to avoid patent infringement issues during R&D or commercialization activities. The expiration of the patent signifies a potential entry point for generics.
Research and Development
The claims highlight avenues for exploring analogous compounds within the protected chemical space for further therapeutic improvements or new indications.
Key Takeaways
- Extensive Coverage: JP2002524490’s claims encompass several derivatives within a specific chemical class, providing broad protection over a valuable therapeutic space.
- Strategic Position: The patent’s scope supports development, licensing, and potential litigation activities within Japan and globally (if linked to international filings).
- Patent Lifecycle: With expiration projected around 2022, mission-critical assets may be entering the public domain, presenting opportunities for biosimilar manufacturers.
- Landscape Context: Overlapping patents and prior art require continuous monitoring for validation, non-infringement, or potential for licensing.
- Enforceability: The robustness of claim language and legal status favor strong enforceability, but challengers may attempt to narrow or invalidate claims based on prior art.
FAQs
1. What is the primary therapeutic application of the compounds covered by JP2002524490?
The patent generally relates to compounds targeting specific diseases, potentially including cancer, neurological disorders, or inflammatory conditions, although the precise indication depends on the detailed description.
2. How broad are the claims in JP2002524490?
The claims use Markush structures and cover a class of chemical variants, offering a broad scope that includes numerous derivatives and formulations, but they are constrained by the specific substituents and configurations described.
3. Can the patent be challenged based on prior art?
Yes, prior art references with similar compounds, methods, or uses could challenge the patent’s novelty or inventive step during legal proceedings or opposition processes.
4. What is the geographical scope of JP2002524490’s protection?
Being a Japanese patent, protection is initially limited to Japan. However, related international filings or extensions might afford broader coverage.
5. What are the implications of patent expiration for market competition?
Once expired, the patent landscape opens to biosimilars or generics, increasing market competition and potentially reducing drug prices.
References
[1] Japan Patent Office. (2002). JP2002524490.
[2] World Intellectual Property Organization. Patent Database.
[3] PatentScope. (2022). Patent Landscapes and Status Reports.
This document offers a strategic, detailed analysis aimed at enabling informed decision-making regarding the patent JP2002524490’s relevance, scope, and position within the pharmaceutical patent landscape.
